Skip to main content
. 2023 Mar 7;14:886601. doi: 10.3389/fimmu.2023.886601

Figure 1.

Figure 1

ATRvD1 treatment restores bleomycin (BLM)-induced lung morphology and inflammation. (A) Representative lung sections from saline (SAL) (left), BLM (center; 0.06 U/mouse in a final volume of 30 μl of SAL), and BLM plus ATRvD1 treatment (right; on day 7, 2.5 μg/kg and a booster on day 10 with 0.5 μg/kg) obtained 14 days after BLM injection and stained with hematoxylin and eosin. Scale bar = 50 μm. (B, C) Inflammatory cells and cytokines, MMP-9, and TIMP-1 were quantified in the BAL fluid and lung tissue, respectively, 14 days after SAL, BLM, or BLM plus ATRvD1 treatment as described in (A). Results represent mean + SEM from two independent experiments. *P ≤ 0.05 vs. the SAL group; # P ≤ 0.05 vs. the BLM group.